The treatment used in this study is Gardasil 9, which is a vaccine given through intramuscular injection. This vaccine protects against nine different types of HPV. Study participants will receive up to two doses of the vaccine over a period of 12 months. The vaccine contains small particles that look like the virus but cannot cause infection – these are called virus-like particles.

The main purpose of this research is to understand how the body’s immune response to the vaccine works by studying urine samples before and after vaccination. Researchers will examine these samples to see how effectively the vaccine-induced antibodies can prevent the virus from infecting cells. This will help better understand how the vaccine provides protection against HPV infection.

The purpose of the study is to assess how effective the Cervarix vaccine is in preventing HPV infections. Participants in the study will receive the vaccine through an injection into the muscle. The study will compare the presence of HPV types 16 and 18 in those who have been vaccinated with those who have not. This will help researchers understand the vaccine’s effectiveness in real-world conditions.

Participants will be involved in the study for a period of up to 24 months. During this time, they will receive the vaccine and attend follow-up visits to monitor their health and check for the presence of HPV. The study aims to provide valuable information on the benefits of the Cervarix vaccine in preventing HPV infections, which can lead to serious health problems if left untreated.

The purpose of the study is to determine if the Gardasil 9 vaccine can reduce the occurrence of persistent oral infections caused by the specified HPV types over a period of six months or longer. Participants in the study will receive either the vaccine or a placebo and will be monitored for any infections and their immune response to the vaccine. The study will also assess the safety of the vaccine by tracking any side effects or adverse events that participants may experience.

Throughout the study, participants will be asked to attend regular check-ups to monitor their health and the effectiveness of the vaccine. The study aims to provide valuable information on the potential benefits of the Gardasil 9 vaccine in preventing HPV-related oral infections in adult males. The study is expected to continue until 2028, allowing researchers to gather comprehensive data on the vaccine’s long-term effects and safety.

The purpose of this study is to compare the effectiveness of 2LPAPI with a placebo in clearing high-risk HPV infections over a period of 12 months. Participants in the study will receive either the 2LPAPI treatment or a placebo, and their progress will be monitored at regular intervals. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will have follow-up visits to check the status of the HPV infection and any changes in their health. The main goal is to see if the 2LPAPI treatment can effectively clear the HPV infection by the end of the study period. Additionally, the study will monitor the safety of the treatment by recording any side effects or adverse events that may occur. This research aims to provide valuable information on a potential new treatment option for those affected by high-risk HPV infections.

Participants in the study will receive the Gardasil 9 vaccine in three doses. The study will collect samples from different parts of the body, such as the cervix, anus, vulva, urine, and mouth, before and after each vaccine dose. These samples will help researchers understand how the vaccine affects the virus’s ability to infect and spread. The study will also look for the presence of antibodies, which are proteins made by the body to fight infections, in these samples. This will help determine if the vaccine is effective in reducing the virus’s ability to cause infection.

The study is open-label, meaning that both the participants and the researchers know which treatment is being given. It is non-randomized, so all participants will receive the Gardasil 9 vaccine rather than being randomly assigned to different groups. The study aims to provide valuable information on how well the vaccine works in reducing the spread of HPV in women who are already infected with certain types of the virus. This information could be important for understanding how to better prevent HPV-related diseases in the future.